Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01246063 · ClinicalTrials.gov registry record · Phase 1
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01246063 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 40 participants.
The verdict
NCT01246063, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The aim of this phase I/II trial is to determine the maximal tolerated dose (MTD) of carfilzomib together with pegylated liposomal doxorubicin hydrochloride (PLD) with or without dexamethasone, and then to establish the efficacy and safety of this novel combination in patients with relapsed or refractory multiple myeloma
Interventions
- DRUG Dexamethasone
- DRUG carfilzomib
- DRUG pegylated liposomal doxorubicin (PLD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-05-14 |
| Est. Completion | 2018-03-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01246063
The ClinicalTrials.gov registry entry for NCT01246063 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01246063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01246063 about?
NCT01246063 is a clinical study titled "Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma". The aim of this phase I/II trial is to determine the maximal tolerated dose (MTD) of carfilzomib together with pegylated liposomal doxorubicin hydrochloride (PLD) with or without dexamethasone, and then to establish the efficacy and safety of this novel combination in patients with relapsed or refra...
What is the current status of trial NCT01246063?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2012-05-14. Estimated completion is 2018-03-23.
What interventions are being tested in trial NCT01246063?
The interventions under investigation include: Dexamethasone (DRUG), carfilzomib (DRUG), pegylated liposomal doxorubicin (PLD) (DRUG).
Who is sponsoring clinical trial NCT01246063?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.